Clastogenic action of ellipticine over the cell cycle of human lymphocytes and influence of posttreatments with caffeine and ara-C at G2.
The clastogenic potential of the intercalating compound ellipticine, an antitumor alkaloid, has been demonstrated in mammalian cells. To characterize the mechanism of action of this drug over the cell cycle, human lymphocyte cultures from 2 healthy donors were treated with 3 micrograms/ml ellipticine in 30-min pulses during different phases of the cell cycle and analyzed for chromosomal aberrations and sister-chromatid exchanges. The G2 phase was most sensitive in terms of induction of aberrations, followed by S and G1. Chromatid-type aberrations were the most common type of chromosomal damage. Induction of SCEs was significantly high only after treatment at G1, when the frequencies of SCEs doubled. The post-treatment effect of lymphocytes with inhibitors of DNA repair, 10(-3) M caffeine and 5 x 10(-6) M 1-beta-D-arabinofuranosylcytosine, was also tested by adding 3 micrograms/ml ellipticine at G2 in 30-min pulses and immediately followed by caffeine and/or ara-C during the last 3 h before harvesting. Three experiments performed on blood from 3 donors showed a moderate potentiation effect on the frequency of chromatid-type aberrations (about 2-3 times) by both inhibitors. Likewise, a 3-fold increase was observed in the frequencies of chromosomal aberrations when caffeine and ara-C were combined. The present data demonstrate that posttreatment with caffeine and ara-C at G2 can modify the response of human lymphocytes treated with ellipticine by increasing the clastogenic action of this compound or by changing the cell-cycle progression.
Sakamoto-Hojo
E T
ET
Dep. Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirão Preto-USP, Brazil.
Takahashi
C S
CS
D002110:Caffeine / Q000009:adverse effects*; D002453:Cell Cycle / Q000187:drug effects*; D002869:Chromosome Aberrations; D003561:Cytarabine / Q000494:pharmacology; D004247:DNA / Q000187:drug effects*; D004260:DNA Repair / Q000187:drug effects; D004357:Drug Synergism; D004611:Ellipticines / Q000494:pharmacology*; D016195:G2 Phase / Q000187:drug effects; D006801:Humans; D009153:Mutagens / Q000494:pharmacology*; D012854:Sister Chromatid Exchange / Q000187:drug effects
D004611:Ellipticines; D009153:Mutagens; D003561:Cytarabine; C034192:ellipticine; D002110:Caffeine; D004247:DNA